Drug intelligence / Profile preview

ASC31

Development stage: Preclinical
Lead developer: Ascletis Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

ASC31 is a novel dual agonist targeting both glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR). It is developed by Ascletis Pharma for the treatment of obesity. ASC31 demonstrates favorable pharmacokinetics in non-human primates and promising efficacy in diet-induced obese mice. It is part of Ascletis' Ultra-Long-Acting Platform (ULAP) for injectable peptides.

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on ASC31.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC31.

Explore the full profile